Evidence map›Paper›PMID 40533538›Full record

ReviewEMBO reports2025

Insights from human NF-κB knockouts.

Maximilian Pfisterer, Jan Dreute, M Lienhard Schmitz

Abstract readReview
In one paragraph

Review in EMBO reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A Suite of EightbioRxiv : the preprint server for biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maximilian Pfisterer *Institute of Biochemistry, Justus-Liebig-University, Giessen, Germany.ORCID 0000-0003-3573-906X
Jan Dreute *Institute of Biochemistry, Justus-Liebig-University, Giessen, Germany.ORCID 0000-0002-4708-2678
M Lienhard SchmitzInstitute of Biochemistry, Justus-Liebig-University, Giessen, Germany. lienhard.schmitz@uni-giessen.de.ORCID 0000-0002-6984-7192

Funding

Deutsche Forschungsgemeinschaft (DFG) 390649896Deutsche Forschungsgemeinschaft (DFG) 416910386European Commission (EC) CA23119Forschungscampus Mittelhessen Experimentierräume
6 · The paper itself

Abstract

The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in humans now allow initial insights into non-essential human genes in which both alleles carry mutations that prevent protein expression or function. Here, we compiled the non-essential genes identified in various sequencing studies and analyzed the occurrence of knockouts in the human NF-κB signaling system. This revealed a lower knockout frequency in the NF-κB system compared to the entire genome. Since drugs inhibiting NF-κB pathway components were unsuccessful in clinical trials so far, the naturally occurring knockouts of NF-κB and its upstream regulators could provide new candidates for therapeutic intervention. To investigate the potential functional importance of posttranslational modifications (PTMs) occurring on NF-κB components, we analyzed not only their evolutionary conservation but also, as a second criterion, their genetic constraint in the sequenced individuals. This approach revealed the absence of missense mutations at key modification sites involved in NF-κB activation and identified additional candidate sites for future studies.

Indexed as

NF-kappa BGene Knockout TechniquesGenome, HumanHumansMutationProtein Processing, Post-TranslationalSignal TransductionNF-kappa BGene EssentialityKnockoutLoss-of-functionNF-κBSignaling

Identifiers

PMID40533538
PMCPMC12287409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.